{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:26Z","timestamp":1793371526330,"version":"4.5.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8164-26","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:11:59Z","timestamp":1791411119000},"source":"Crossref","is-referenced-by-count":1,"title":["An Active Cytomegalovirus Infection and Epstein-Barr Virus Reactivation Complicated by Cytomegalovirus Meningitis and Virus-Associated Hemophagocytic Lymphohistiocytosis during Methotrexate and Upadacitinib Therapy in a Patient with Rheumatoid Arthritis"],"prefix":"10.2169","author":[{"given":"Kazuki","family":"Tomiyama","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Fukami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Yukishima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Harigai M, Kaneko Y, Tanaka E, et al. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: secondary publication. Mod Rheumatol 35: 387-401, 2025.","DOI":"10.1093\/mr\/roaf006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fleischmann R, Swierkot J, Penn SK, et al. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open 10: e004007, 2024.","DOI":"10.1136\/rmdopen-2023-004007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391: 2513-2524, 2018.","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol 18: 253-261, 2022.","DOI":"10.1080\/1744666X.2022.2014323"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131, 2007.","DOI":"10.1002\/pbc.21039"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66: 2613-2620, 2014.","DOI":"10.1002\/art.38690"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Xu Q, He L, Yin Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol 14: 1241954, 2023.","DOI":"10.3389\/fphar.2023.1241954"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Saito S, Suzuki K, Yoshimoto K, et al. Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol 9: 621, 2018.","DOI":"10.3389\/fimmu.2018.00621"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. McNab F, Mayer-Barber K, Sher A, Wack A, O\u2019Garra A. Type I interferons in infectious disease. Nat Rev Immunol 15: 87-103, 2015.","DOI":"10.1038\/nri3787"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lebon D, Dujardin A, Caulier A, et al. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res 125: 107005, 2023.","DOI":"10.1016\/j.leukres.2022.107005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakajima H, Takayama A, Ito T, Yoshikawa T. Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy. BMJ Case Rep bcr2013009731, 2013.","DOI":"10.1136\/bcr-2013-009731"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ramasamy BR, Charles P, Johnson D, Frauman A. Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab. BMJ Case Rep bcr-2017-220184, 2017.","DOI":"10.1136\/bcr-2017-220184"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sato T, Kitamura R, Kaburaki T, Takeuchi M. Retinitis associated with double infection of Epstein-Barr virus and varicella-zoster virus: a case report. Medicine (Baltimore) 97: e11663, 2018.","DOI":"10.1097\/MD.0000000000011663"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 6: e630-e637, 2019.","DOI":"10.1016\/S2352-3026(19)30156-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol 12: 614704, 2021.","DOI":"10.3389\/fimmu.2021.614704"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8164-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:11:37Z","timestamp":1791605497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8164-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8164-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8164-26"}}